Beta Bionics

BBNX

Market cap $911M

IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025.

Beta Bionics, Inc. (NASDAQ:BBNX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Stephen Feider - CFO, Treasurer & Secretary Sean Saint - President, CEO & Director Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Stephen Feider CFO, Treasurer & Secretary I'm Stephen, and this is Sean. Patrick Wood MD of Equity Research Welcome.

Beta Bionics' iLet product is gaining traction, but management's conservative guidance has created uncertainty around future growth and competitiveness. Recent quarters showed strong revenue growth and improved guidance, but operating losses remain substantial, and operating leverage is lacking. The company's valuation has rebounded sharply, now trading at about 6 times sales, reflecting renewed optimism but also higher expectations.

IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at three upcoming investor conferences (all Eastern Time): Wells Fargo 20th Annual Healthcare Conference on Thursday, September 4, 2025 at 3:45pm Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:50pm Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 9:40am The presentations at the Wells Fargo and Morgan Stanley conferences will be webcast live.

Beta Bionics, Inc. (NASDAQ:BBNX ) Q2 2025 Earnings Call July 29, 2025 4:30 PM ET Company Participants Blake Beber - Head of Investor Relations Sean T. Saint - President, CEO & Director Stephen H.

Beta Bionics (BBNX) Q2 Revenue Soars 54%

IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025.

IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time).

Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.

IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S.